Clinical Trial Failure Risk: Zevra's drug candidates may not achieve their primary or secondary endpoints in ongoing or future clinical trials, leading to program delays, discontinuation, or failure to demonstrate sufficient efficacy or safety for regulatory approval.

Regulatory Approval Risk: Despite positive clinical data, Zevra's investigational therapies may not receive approval from regulatory bodies such as the FDA or EMA due to concerns about safety, efficacy, manufacturing processes, or the interpretation of clinical results, preventing them from reaching the market.

Commercialization and Market Adoption Risk: Even if approved, Zevra's products may not gain widespread market acceptance or achieve anticipated sales volumes. This could be due to competition, limited physician adoption, challenges with patient access, or unfavorable reimbursement policies from payers, particularly for rare disease treatments.